# Synergistic Anti-tumor Effect of ChangTai Keli for Colon Cancer Patients

> **NCT02510118** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Nanjing NingQi Medicine Science and Technology Co., Ltd.** · enrollment: 360 (estimated)

## Conditions studied

- Colon Cancer

## Interventions

- **DRUG:** mFOLFOX6
- **DRUG:** XELOX
- **DRUG:** Placebo ChangTai Keli
- **DRUG:** ChangTai Keli

## Key facts

- **NCT ID:** NCT02510118
- **Lead sponsor:** Nanjing NingQi Medicine Science and Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-06
- **Primary completion:** 2016-06
- **Final completion:** 2018-06
- **Target enrollment:** 360 (ESTIMATED)
- **Last updated:** 2015-08-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02510118

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02510118, "Synergistic Anti-tumor Effect of ChangTai Keli for Colon Cancer Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02510118. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*